France Pharmaceuticals & Healthcare Report Q4 2015 - New Report Available

The French economy's moderate growth acceleration will continue to pose upside risks to our pharmaceuticals and healthcare forecasts over a multi-quarter horizon. However, although gradually recovering, the pharmaceutical market is expected to remain in negative growth territory in 2015 and 2016 before resuming expansion and ultimately picking up by the end of our forecast period. While the pharmaceuticals and healthcare sector long-term growth fundamentals bode favourably to drugmakers operating in the country, the slow pace of reforms to the labour market will ensure minimal competitiveness gains in France's operating environment, which will continue to translate in subdued rates of investment, including in the pharmaceutical sector .

Full Report Details at
- http://www.fastmr.com/prod/1047931_france_pharmaceuticals.aspx?afid=301

Headline Expenditure Projections

Pharmaceuticals: EUR33.69bn (USD45.14bn) in 2014 to EUR33.44bn (USD36.79bn) in 2015; -0.7% in local currency terms and -18.5% in US dollar terms. Forecast revised upwards from last quarter.
Healthcare: EUR246.20bn (USD329.91bn) in 2014 to EUR253.46bn (USD278.81bn) in 2015; +3.0% in local currency terms and -15.5% in US dollar terms. Forecast revised upwards from last quarter.

Risk/Reward Index

In Q415 we have revised downwards France RRI score to 70.5 from 71.7 in the last quarter, out of a maximum 100 points. France remains ranked as the third most attractive market to pharmaceutical investors out of 15 markets in Western Europe. The downward revision was due to lower drug spending per capita indices. France's score is boosted by the large multi-billion dollar drug market (market expenditure score of 16.0 out of 20), and large pensionable population (pensionable population score of 8.0 out of 8), but dragged down by poor market expansion (sector value growth score of 0.0 out of 12).

The France Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's France Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the France pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for France, to test other views - a key input for successful budgeting and strategic business planning in the French pharmaceutical and healthcare market.
* Target business opportunities and risks in the French pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in France.
* Assess the activities, strategy and market position of your competitors

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015